These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39269701)

  • 1. Safety analysis of fluoroquinolone drugs in elderly patients over 65 based on FAERS.
    Li Y; Chen L; Tang X; Luo L; Wang C
    Expert Opin Drug Saf; 2024 Sep; ():1-13. PubMed ID: 39269701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety analysis of quinolones use in minors-based on the FAERS database.
    Li Y; Wang J; Wang C; Chen L
    Front Med (Lausanne); 2024; 11():1437376. PubMed ID: 39267976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
    Huruba M; Farcas A; Leucuta DC; Bucsa C; Sipos M; Mogosan C
    Sci Rep; 2021 Jul; 11(1):14375. PubMed ID: 34257376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system.
    Arabyat RM; Raisch DW; McKoy JM; Bennett CL
    Expert Opin Drug Saf; 2015; 14(11):1653-60. PubMed ID: 26393387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
    Nicholls C; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib.
    Wu Y; Wei M; Zhang J
    Front Pharmacol; 2023; 14():1200254. PubMed ID: 37663269
    [No Abstract]   [Full Text] [Related]  

  • 9. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety assessment of basiliximab using real-world adverse event data from the FDA Adverse Event Reporting System Database: A retrospective observational study.
    Chen S; Ma X; Zhang J
    Medicine (Baltimore); 2024 Sep; 103(36):e39537. PubMed ID: 39252278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database.
    Jiang Y; Zhou L; Shen Y; Zhou Q; Ji Y; Zhu H
    J Affect Disord; 2024 Feb; 346():223-229. PubMed ID: 37956832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system.
    Taher MK; Alami A; Gravel CA; Tsui D; Bjerre LM; Momoli F; Mattison D; Krewski D
    Expert Opin Drug Saf; 2022 Feb; 21(2):269-276. PubMed ID: 34641748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy related adverse events and congenital disorders associated with fluoroquinolones: A real-world pharmacovigilance study of the FDA adverse event reporting system (FAERS).
    Xiang DC; Xie WL; Cheng GY; Yue M; Du XY; Jiang J
    Heliyon; 2024 Sep; 10(18):e37547. PubMed ID: 39309803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups.
    He Y; Guan X; Zhang Y; Zhu Z; Zhang Y; Feng Y; Li X
    Expert Opin Drug Saf; 2024 Dec; 23(12):1561-1569. PubMed ID: 38676389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database.
    Shu Y; Zhang Q; He X; Liu Y; Wu P; Chen L
    Front Pharmacol; 2022; 13():990241. PubMed ID: 36147351
    [No Abstract]   [Full Text] [Related]  

  • 16. A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS).
    Tang L; Sun C; Liu W; Wu H; Ding C
    Front Pharmacol; 2024; 15():1362484. PubMed ID: 38384285
    [No Abstract]   [Full Text] [Related]  

  • 17. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
    Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
    Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of proteasome inhibitor drugs for the treatment of multiple myeloma post-marketing: a pharmacovigilance investigation based on the FDA adverse event reporting system.
    Yu D; Cheng T; Liu T; Xu W; Liu D; Dai J; Cai S; Guan Y; Ye T; Cheng X
    Expert Opin Drug Saf; 2024 Aug; ():1-8. PubMed ID: 39157912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.